Immix Biopharma ($IMMX) is back on the radar ahead of the expected late-September 2026 NEXICART-2 update, but the setup looks considerably different from when we last covered the company.
The underlying clinical story remains NXC-201 in relapsed/refractory AL amyloidosis, where complete response rates increased from 70% in the initial ASCO data to 75% at ASH, reaching 95% at the six-month follow-up.
What has changed is everything surrounding that dataset.
NEXICART-2 is now fully enrolled at 45 patients, Immix has more than $225M in cash, institutional ownership has increased materially, the stock has broken out ahead of the catalyst, and options activity is beginning to price considerably more event risk.
That combination makes the September update more interesting than a simple continuation of the prior readout.
The first 20 patients already established the bull case.
The next 25 determine how much of it survives.
The September update is anticipated to include data on 45 patients. It is worth noting that NXC-201 reported approximately a 70% complete response rate at ASH last year in the first 20 patients, with the CR rate increasing as patient follow-up matured. We will be looking for a similar or better early response profile from the additional 25 patients in September.
The focus also remains on MRD negativity and whether patients continue to show no disease-causing plasma cells in the bone marrow as follow-up approaches 12 months. AL amyloidosis is a devastating disease with substantial mortality in advanced patients, and NXC-201 has consistently shown approximately a 70% CR rate around 90 days after initial treatment.
Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.
We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).
Be sure to SUBSCRIBE to not miss.
HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS
While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.
This is not financial advice so you will have to make your own call on how to best play these events. Our aim is simply to flag catalysts with high projected volatility.
🚨 ALERT: NEXICART-2 45-Patient Update - NXC-201 in R/R AL Amyloidosis
📅 TIMING: Late September 2026
📈 IMPLIED MOVE: ~±80%
BACKGROUND:
